Review Article

Alpha-Fetoprotein and Hepatocellular Carcinoma Immunity

Xiaoping Wang1 and Qiaoxia Wang2

1Laboratory of Molecular Biology & Pathology, Shaanxi University of Chinese Medicine, Xianyang, Shaanxi 712046, China
2Department of Infectious Diseases, Xian Central Hospital, Xi’an, Shaanxi 710000, China

Correspondence should be addressed to Xiaoping Wang; wxpphd@aliyun.com

Received 3 December 2017; Revised 25 January 2018; Accepted 18 March 2018; Published 1 April 2018

Academic Editor: Maikel P. Peppelenbosch

Copyright © 2018 Xiaoping Wang and Qiaoxia Wang. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Hepatocarcinoma is one of the most prevalent gastroenterological cancers in the world with less effective therapy. As an oncofetal antigen and diagnostic marker for liver cancer, alpha-fetoprotein (AFP) possesses a variety of biological functions. Except for its diagnosis in liver cancer, AFP has become a target for liver cancer immunotherapy. Although the immunogenicity of AFP is weak and it could induce the immune escapes through inhibiting the function of dendritic cells, natural killer cells, and T lymphocytes, AFP has attracted more attention in liver cancer immunotherapy. By in vitro modification, the immunogenicity and immune response of AFP could be enhanced. AFP-modified immune cell vaccine or peptide vaccine has displayed the specific antitumor immunity against AFP-positive tumor cells and laid a better foundation for the immunotherapy of liver cancer.

1. Introduction

Hepatocellular carcinoma (HCC) is one of the most common tumors in the world, with a new incidence of up to 600,000 cases per year [1, 2]. This malignancy is becoming more prevalent in Asia because of the high incidences of hepatitis B and C infections [3, 4]. Due to the insidious onset and long incubation period of HCC, patients usually get intermediate or advanced stage with poor prognosis. At present, the treatments of liver cancer mainly rely on surgical resection, liver transplantation, local ablation, chemoembolization, and molecular targeted therapy, but the effects of these strategies are not ideal and the mortality is still high [5, 6]. Therefore, there is an urgent need to develop effective adjuvant therapies that may prolong the life and improve the quality of patients with HCC.

Immunotherapy of HCC could stimulate the identification of specific tumor antigen, inhibit the proliferation of cancer cells, produce memory lymphocytes and prevent recurrence, so the immunotherapy of HCC has attracted more attention in recent years. In this paper, the research progress on the immunotherapy of alpha-fetoprotein (AFP) and HCC is reviewed.

2. Significance of Alpha-Fetoprotein Expression in Hepatocellular Carcinoma

Alpha-fetoprotein is a kind of glycoprotein, derived from embryonic endoderm tissue cells. AFP content in fetal serum is high and gradually decreases to the level of adults after birth. The low content of AFP in the adult blood is mainly due to the loss of the ability to synthesize AFP in mature hepatocytes. When transformed, the liver cancer cells can regain the ability to synthesize AFP. Besides liver cancer, malignant tumors from stomach, pancreas, and reproductive system are often accompanied by a small amount of increased AFP. In general, AFP is produced only at low levels after birth; however, majority of human HCC overexpress high level of AFP in eastern populations [6, 7]. Therefore, the HCC patients with AFP negative or weak positive in serum is usually consistent with the characteristics of high differentiated cancers [6, 7].

Combining detection of AFP with new diagnostic markers increases the sensitivity and specificity to diagnose HCC. For instance, combination of AFP and lens culinaris lectin detection resulted in increased specificity and sensitivity in diagnosing HCC [8, 9]. With the progress of clinical laboratory techniques, the new liver biomarkers have displayed
important roles in the diagnosis of liver cancer. Abnormal prothrombin des-γ-carboxy prothrombin (dCP) and alpha-L-fucosidase (AFU) are available in diagnosing AFP-negative HCC [10, 11]. Combining AFP-L3 with Golgi protein 73, the diagnostic sensitivity was 94%, specificity was 93.1%, and the accuracy rate of diagnosis was 93.3% in HCC patients, greatly improving the early diagnosis rate of liver cancer [12, 13].

In addition to being an oncofetal antigen and diagnostic marker for liver cancer, AFP possess a variety of biological functions, such as transport function similar to the class of albumin family, transporting metal ions, drugs, bilirubin, and steroids [1-4].

3. AFP and Immune Escape Mechanism of Hepatocellular Carcinoma

Liver cancer cells can modify their own surface antigen and change the microenvironment around the tumor lesion to implement their immune escape. Exogenous AFP can not only promote the proliferation of hepatocellular carcinoma cells and the formation of tumor blood vessels, but also enhance the antiapoptosis effect of cancer cells [14-18].

Thus, AFP plays an important role in the development and progression of liver cancer. Cellular immunity is the main immune mechanism of anticancer [19]. Dendritic cells, natural killer cells, and T lymphocytes are involved in immune surveillance [19]. It is confirmed that AFP could affect the three important immune cells to exert their antitumor effects [14, 15].

DC cells own the function of high uptake, processing and presenting antigen, which are the only antigen-presenting cells (APC) directly activating naive T cells. AFP can inhibit the maturation and induce apoptosis of DC cells, so that cancer cells could escape the immune surveillance. Researches demonstrated that when peripheral blood mononuclear cells were cultured in normal umbilical cord blood AFP (nAFP) and tumor derived AFP (tAFP) separately, the phenotype and function of DC cells were altered. Tumor derived AFP could significantly inhibit the differentiation of DCs, and the DC cells restricted by tAFP still maintained the immature mononuclear cell-like morphology [20]. Moreover, the DCs apoptosis index and Caspase-3 expression were significantly increased after AFP treatment [20, 21]. In addition to the increased expression of Caspase-3, p38 mitogen-activated protein kinase (MARK) expression was also increased in DC cells [20, 21]. When AFP was incubated with DCs from human peripheral blood, the cells were found to express Caspase-3 and p38-MARK, which would induce apoptosis and inhibit the maturation of DC cells, thus resulting in the immune escape of cancer cells [21, 22].

NK cell is an important component of the innate immune system, which is the first line of defense against infections and tumors. NK cells could express a variety of surface receptors, including activating receptors (NKG2D, NKp30, NKp44, NKp46) and inhibitory receptors (KIR2DL3/CD158b). When recognizing the tumor cells, the expression of activating receptors increases and the expression of inhibitory receptors decreases, which lead to the enhancement of the antitumor effects. IL-12 is able to stimulate the expression of NKG-2D on the surface of NK cells and improve the toxic effect of NK cells. After binding to its ligand, NKG2D activates NK cells and exerts an immune response [23]. Therefore, when the mice loaded with liver cancer cells were vaccinated with IL-12, it was found that the expression of activating receptors of NK cells increased while inhibitory receptors decreased, and IFN-γ content elevated, thus suppressing the tumor growth [22].

The function of NK cells could also be affected by AFP. AFP does not directly damage the function of NK cells, but through inhibiting the maturation of DC cells, DC cells reduce the secretion of the amount of IL-12, then indirectly inhibiting NK cells [24, 25].

DCs could activate AFP-specific T cells significantly in vitro and in vivo. The main mechanism is the specific upregulation of IL-2, IFN-γ, TNF-α, granzyme, and perforin and downregulation of IL-10, which suppresses the immune function [34]. CD4+ T cells as Th helper lymphocytes can assist CD8+ cytotoxic T cells (CTLs) to exert cytotoxic effect. AFP-specific CD4+ T and CD8+ T cells kill the cancer cells mainly relying on the granzyme and perforin pathways without affecting the Fas/Fasl pathways [25, 34]. Although AFP is expected to play a certain role in antitumor immunity, it is still useless to stimulate the immune cells and produce substantial effects on cancer cells due to its weak immunogenicity. On the contrary, AFP contributes to the promotion of the change of CD4+ T and CD8+ T cell proportion and leads to tumor immune escape [33, 35]. Researchers measured CD4+ T (Treg cells) in HCC patients, chronic hepatitis B patients, and healthy population and found that the quantity of Treg cells was high in the peripheral blood of HCC patients, which could inhibit antitumor immune responses and affect the function of CD8+ T lymphocytes [33, 35]. By multiple ways suppressing the immune cells, HCC cells are able to escape immune surveillance and continue to grow in the body, showed as Figure 1, Box 1.

4. Role of AFP in Hepatocellular Carcinoma Immunity

 AFP plays an important role in the regulation of cell proliferation, which may be mediated by receptor, signal transportation, and gene expression. Some studies have indicated that AFP is mainly present on the cell surface or inside the cytoplasm, and AFP in the cytoplasm is mediated by the endocytosis of the receptor into the cell [36]. In the AFP-positive tissue, AFP receptor (AFPR) is also positive, while in normal tissue or AFP-negative tissue, AFPR is also negative, indicating that the expression of AFP receptors in the cells is associated with AFP [36]. The promotion of tumor proliferation of AFP/AFPR is dependent on the CAMP-PKA pathway and the induction of Ca2+ influx [37]. AFP/AFPR brings about Ca2+ influx, so the intracellular Ca2+ increases, then the intracellular CAMP correspondingly rises, enhancing protease A activity, prompting DNA synthesis, and achieving the purpose of tumor cell proliferation [37].

The activation of immune response requires enhancing the ability of antigen-presenting cell uptake, processing and presenting antigen, so that T lymphocytes could be activated...
Promotion of cancer cell proliferation mediated by the binding of AFP receptors (AFPR), the activation of PI3K/AKT signal pathway, the stimulation of oncogene protein, and the dysfunction of PTEN antioncogene protein [26–32].

Promotion of tumor invasion and metastasis via upregulating expression of metastasis-related proteins, such as keratin 19 (K19), epithelial cell adhesion molecule (EpCAM), matrix metalloproteinase 2/9 (MMP2/9), and CXC chemokine receptor 4 (CXCR4) [26, 27, 33].

Promotion of tumor angiogenesis by increasing expression of vascular endothelial growth factor (VEGF), vascular endothelial growth factor receptor 2 (VEGFR-2), and matrix metalloproteinases-2/9 (MMP2/9) [16, 26].

Antitumor apoptosis by blocking the Fas/FasL, caspase-3, and PI3K/AKT signaling pathways of tumor [13, 14, 16, 19, 27–29].

Escaping from immune surveillance via triggering the Fas/FasL interaction between tumor cells and lymphocytes; inhibiting the maturation and inducing apoptosis of DC cells; reducing the secretion of the amount of IL-12 from DC cells, thus indirectly inhibiting NK cell; promoting the change of CD4⁺ T and CD8⁺ T cell proportion; and enhancing the quantity of Treg cells [20–25, 33–35].

Box 1: The mechanisms of AFP promoting cancer cell proliferation.

**Figure 1:** Mechanisms of AFP promoting the growth of cancer cells. AFP promoted cancer cell proliferation, invasion, and metastasis by inducing apoptosis of immune cells, binding AFP receptors (AFPR), and activating signal transduction pathways.

and the immune response is elicited [38]. Since AFP promotes the proliferation of liver cancer, it could be a new target for the immune therapy of liver cancer. However, despite exposure to high plasma levels of AFP during hepatocellular carcinoma development, only low immunity is mounted against the protein [36, 37]. How to overcome the immune tolerance of AFP is the key point of antitumor immunity. Studies have dissected the immunodominant epitopes of AFP in order to effectively use this protein for immunotherapy of AFP expressing tumors [39–41]. Researches confirmed that these identified epitope peptides could be recognized by the T cells in vitro and generated AFP-specific CTLs [39, 40]. Some epitopes of AFP have been found to be recognized by the major histocompatibility complex (MHC) class I or II molecular of APC cells [41]. When presented to CD8⁺ T or CD4⁺ T lymphocytes, the epitopes activated specific CTLs to secret high levels of TNF-α and IFN-γ and stimulated specific immune response against hepatocellular carcinoma [41, 42]. DC cells modified by the hAFP peptide (137–145) could successfully induce the peripheral blood mononuclear cells to be specific CTLs, and the immune response was better than that of the intact hAFP alone [43, 44]. Thus, AFP could be a promising candidate for immunotherapy. In this way, we may overcome the immune tolerance of AFP and eliminate the cancer cells.

Tumor immunity has the advantages of high efficiency and low toxicity, whose purpose is to start or restart the immune response independently and continuously and avoid the damage of autologous tissue cells. At present, clinical studies have confirmed that immunotherapy can improve the prognosis of patients with HCC [43]. It was found that when DC cells were incubated with AFP and IL-12, specific
Biomarker for HCC in clinical diagnosis, the evaluation of response to therapy, and the surveillance for tumor recurrence [5–12]. DNA vaccine constructed by the whole or partial AFP gene alone or fused with cytokines or modulation adjuvant such as GM-CSF, IL-2, and HSP70 [57–68]. Protein vaccine established via the whole or partial AFP protein alone or cross-linked with cytokines or modulation adjuvant and so forth [47, 49, 50]. Peptide vaccine recombined by AFP epitope peptides alone or combined with cytokines or modulation adjuvant and so forth [44–47, 49, 50, 67]. DC cell vaccine activated by pulsed with AFP protein or epitope peptides alone or combined with other TAAs, cytokines, or modulation adjuvant and so forth [45–48, 69–73].

Box 2: AFP and tumor immunity.

Figure 2: AFP—a sword with two blades. As an oncofetal antigen and diagnostic marker for liver cancer, AFP is a sword with two blades. AFP promoted tumor proliferation, invasion, angiogenesis, and escaping from immune surveillance, which could be an ideal target for immunotherapy. On the other side, AFP-modified DNA, protein, peptide vaccine, or DC cell vaccine displayed the specific antitumor immunity against AFP-positive liver cancers.

T lymphocytes were activated, resulting in a large number of IL-12 and TNF produced, and specifically attacking HCC cells. The study indicated that DC cells activated by AFP could be made for DC vaccine to induce specific immune effect [45–48]. Research found that the combination of the “internal immune adjuvant” heat shock protein 70 (HSP70) with AFP, forming a HSP70-AFP complex, enhanced AFP immunogenicity and stimulated the immune system to exert its effect [49, 50]. Heat shock protein has the property of “molecular chaperone,” which can help the protein fold, transportation, repair, and degrade. Heat shock protein 70 can present antigen, activate the immune cells, and promote the transformation of Th0 cells to Th1. The tumor HSP70 may combine with a variety of tumor antigen peptides and present multiple antigen epitopes to T cells. HSP70 could activate stronger DC cells response and gain a large amount of cytokine release from the polyclonal T cells [51–53]. Studies have verified that the C-terminal of the HSP70 has immunogenicity and can stimulate the immune cells to produce chemokines, which is able to induce DC mature [51, 52]. The N-terminal of HSP70 plays an important role in presenting antigen peptide. The HSP70 presents antigen to APC cells by HSP70-peptide complexes, then activating CTLs by the interaction with MHC-class I molecules, promoting DC cells and macrophages to secrete inflammatory cytokines, upregulating CD8+ T cells and IFN-γ content, and lowering the concentration of TGF-β1 [52].

5. Application of AFP in the Immunotherapy of Hepatocellular Carcinoma

Liver cancer vaccine aims to make use of HCC cells or antigen to induce the specific immune response, achieving the purpose of prevention and treatment of liver cancer. AFP as a tumor-associated antigen can promote the development of cancer and affect the expression of oncogene through the change of cAMP and Ca²⁺ concentration via binding with the cell membrane receptor [37]. Researches indicated that blocking AFP could inhibit the proliferation of hepatoma cells and induce apoptosis of cancer cells [54–56]. Therefore, AFP has become a new target for the treatment of liver cancer (Figure 2, Box 2).

Recently, there has been an increase in the development of therapeutic vaccines, which are expected to target specific tumor-antigens and boost the host's immune system. Thus, therapeutic vaccines can be considered for the treatment of HCC because about 70% of HCC patients express high levels of the alpha-fetoprotein (AFP), which can serve as a target for immunotherapy [3, 4]. However, because of the suppressing of cellular immunity and the immunologic tolerance of AFP, current treatments targeting AFP are generally weak and do not provide reliable antitumor protection [5]. A number of therapeutic approaches have been described to improve preexisting antitumor immunity, including recombinant plasmid DNA, chimeric virus-like
particles, viral or bacterial vectors expressing AFP proteins, and adoptive transfer of tumor-specific T cells [57–62]. However, therapeutic vaccination is limited due to the low response of the immune system to AFP antigen. Therefore, there is a need to boost the host's immune response against AFP by improving the immunogenicity of AFP.

Polypeptide vaccine has the characteristics of immune response, safety, and easy production. At present, antiviral, anticancer, antimalaria, contraception, and other peptide vaccines are under clinical trials [62, 69–72, 74, 75]. In the immunotherapy of HCC, DC vaccine has showed good application prospects because of its specific and effective immune response in vivo. Current researches have focused on how to enhance the antigen-presenting function of DC cells and exert its strong ability to kill HCC cells [45–48]. Researches showed that DC cells stimulated with zoledronic acid could make T cells secrete large amounts of interferon and enhance the cytotoxic effects on CTLs [72]; DC cells separated from the patients with HCC were cocultured with AFP by improving the immunogenicity of AFP.

With the rapid progress of research, immunotherapy as an adjuvant therapeutic option to be combined with other established treatments such as resection, transplantation, TACE, sorafenib/regorafenib, or nivolumab for the therapeutic design.

6. Summary

AFP plays an important role in the development of hepatocellular carcinoma, which can serve as a target for immunotherapy of HCC. Although the current application of immunotherapy for HCC is still on trial, immunotherapy has achieved certain effect in the treatment of liver cancer. With the rapid progress of research, immunotherapy as an important strategy is expected to bring a great prospect for HCC in the future.

Conflicts of Interest

The authors declare that they have no conflicts of interest to disclose.

Acknowledgments

This work is supported by Scientific Research Program Funded by Shaanxi University of Chinese Medicine and Shaanxi Provincial Education Department (nos. 2007JK233, 2009xj02, 2010JK484, and 14JS025), the Scientific Research Program of Shaanxi Administration of Traditional Chinese Medicine (nos. 15-SCJH001 and JCPT001), and the Natural Science Basic Research Plan in Shaanxi Province of China (nos. 2016JM8023 and 2016JM8150).

References

[1] J. G. Chen and S. W. Zhang, “Liver cancer epidemic in China: past, present and future,” Seminars in Cancer Biology, vol. 21, no. 1, pp. 59–69, 2010.
[2] A. Obed, A. Bashir, and A. Jarrad, “Rapid virological response after early treatment with a combined therapy of ledipasvir and sofosbuvir in HCV genotype 4 after living donor liver transplantation in a HCC downstaged patient: Case report and review of the literature,” American Journal of Case Reports, vol. 17, pp. 672–675, 2016.
[3] J. Bruix, G. J. Gores, and V. Mazzaferro, “Hepatocellular carcinoma: clinical frontiers and perspectives,” Gut, vol. 63, no. 5, pp. 844–855, 2014.
of hepatocellular carcinoma after resection,” *Journal of Clinical Oncology*, vol. 25, no. 18, pp. 2586–2593, 2007.

[36] P. Li, S.-S. Wang, H. Liu et al., “Elevated serum alpha fetoprotein levels promote pathological progression of hepatocellular carcinoma,” *World Journal of Gastroenterology*, vol. 17, no. 41, pp. 4563–4571, 2011.

[37] M.-S. Li, P.-F. Li, S.-P. He, G.-G. Du, and G. Li, “The promoting molecular mechanism of alpha-fetoprotein on the growth of human hepatoma Bel7402 cell line,” *World Journal of Gastroenterology*, vol. 8, no. 3, pp. 469–475, 2002.

[38] I. Mellman, G. Coukos, and G. Dranoff, “Cancer immunotherapy comes of age,” *Nature*, vol. 480, no. 7378, pp. 480–489, 2011.

[39] L. H. Butterfield, A. Koh, W. Meng et al., “Generation of human T-cell responses to an HLA-A2.1-restricted peptide epitope derived from alpha-fetoprotein,” *Cancer research*, vol. 59, no. 13, pp. 3134–3142, 1999.

[40] W. S. Meng, L. H. Butterfield, A. Ribas et al., “Fine specificity analysis of an HLA-A2.1-restricted immunodominant T cell epitope derived from human α-fetoprotein,” *Molecular Immunology*, vol. 37, no. 6, pp. 943–950, 2001.

[41] L. H. Butterfield, W. S. Meng, A. Koh et al., “T Cell Responses to HLA-A*0201-Restricted Peptides Derived from Human Fetal Protein,” *The Journal of Immunology*, vol. 166, no. 8, pp. 5300–5308, 2001.

[42] K. Hiroishi, J. Eguchi, T. Baba et al., “Strong CD8+ T-cell responses against tumor-associated antigens prolong the recurrence-free interval after tumor treatment in patients with hepatocellular carcinoma,” *Journal of Gastroenterology*, vol. 45, no. 4, pp. 451–458, 2010.

[43] J.-H. Lee, Y. Lee, M. Lee et al., “A phase I/IIa study of adjuvant immunotherapy with tumour antigen-pulsed dendritic cells in patients with hepatocellular carcinoma,” *British Journal of Cancer*, vol. 113, no. 12, pp. 1666–1676, 2015.

[44] J.-Y. Yang, X. Li, L. Gao, Z.-H. Teng, and W.-C. Liu, “Co-transfusion of dendritic cells with AFP and IL-2 genes enhances the induction of tumor antigen-specific antitumor immunity,” *Experimental and Therapeutic Medicine*, vol. 4, no. 4, pp. 655–660, 2012.

[45] J.-Y. Yang, D.-Y. Cao, Y. Xue, Z.-C. Yu, and W.-C. Liu, “Improvement of dendritic-based vaccine efficacy against hepatitis B virus-related hepatocellular carcinoma by two tumour-associated antigen gene-infected dendritic cells,” *Human Immunology*, vol. 71, no. 3, pp. 255–262, 2010.

[46] L. H. Butterfield, “Recent advances in immunotherapy for hepatocellular cancer,” *Swiss Medical Weekly*, vol. 137, no. 5–6, pp. 83–90, 2007.

[47] Y. Liu, S. Daley, V. N. Evdokimova, D. D. Zdobinski, D. M. Potter, and L. H. Butterfield, “Hierarchy of a fetoprotein (AFP)-specific T cell responses in subjects with AFP-positive hepatocellular cancer,” *The Journal of Immunology*, vol. 177, no. 1, pp. 712–721, 2006.

[48] A. D. Pardee, H. Yano, A. M. Weinstein et al., “Route of antigen delivery impacts the immunostimulatory activity of dendritic cell-based vaccines for hepatocellular carcinoma,” *Journal for Immuno Therapy of Cancer*, vol. 3, no. 1, article no. 32, 2015.

[49] Z. Li, X. P. Wang, H. P. Lin et al., “Anti-tumor immunity elicited by cross-linking vaccine heat shock protein 72 and alpha-fetoprotein epitope peptide,” *Neoplasma*, vol. 62, no. 5, pp. 713–721, 2015.

[50] X.-P. Wang, H.-P. Lin, Q.-X. Wang, and Y. Gu, “Specific antitumor immunity induced by cross-linking complex heat shock protein 72 and alpha-fetoprotein,” *Cancer Biotherapy and Radiopharmaceuticals*, vol. 27, no. 3, pp. 189–197, 2012.

[51] H. Wang, F. Feng, X.-P. Wang et al., “Dendritic cells pulsed with Hsp70 and HBxAg induce specific antitumor immune responses in hepatitis B virus-associated hepatocellular carcinoma,” *Molecular Medicine Reports*, vol. 13, no. 2, pp. 1077–1082, 2016.

[52] D. S. Wheeler, K. E. Dunsmore, A. G. Denenberg, L. Muething, S. E. Poynter, and H. R. Wong, “Biological activity of truncated C-terminus human heat shock protein 72,” *Immunology Letters*, vol. 135, no. 1-2, pp. 173–179, 2011.

[53] M. Shvetsov and G. Multhoff, “Heat shock protein-Peptide and HSP-based immunotherapies for the treatment of cancer,” *Frontiers in Immunology*, vol. 7, article no. 171, 2016.

[54] T.-M. Hung, R.-H. Hu, C.-M. Ho et al., “Downregulation of alpha-fetoprotein expression by LHX4: A critical role in hepatocarcinogenesis,” *Carcinogenesis*, vol. 32, no. 12, Article ID bgr219, pp. 1815–1823, 2011.

[55] H. Tang, X.-Y. Tang, M. Liu, and X. Li, “Targeting alpha-fetoprotein represses the proliferation of hepatoma cells via regulation of the cell cycle,” *Clinica Chimica Acta*, vol. 394, no. 1-2, pp. 81–88, 2008.

[56] S.-H. Ma, G. G. Chen, J. Yip, and P. B. S. Lai, “Therapeutic effect of α-fetoprotein promoter-mediated tBid and chemotherapeutic agents on orthotopic liver tumor in mice,” *Gene Therapy*, vol. 17, no. 7, pp. 905–912, 2010.

[57] A. Saeki, K. Nakao, Y. Nagayama et al., “Diverse efficacy of vaccination therapy using the α-fetoprotein gene against mouse hepatocellular carcinoma,” *International Journal of Molecular Medicine*, 2004.

[58] C. F. Grimm, D. Ortmann, L. Mohr et al., “Mouse α-fetoprotein-specific DNA-based immunotherapy of hepatocellular carcinoma leads to tumor regression mice,” *Gastroenterology*, vol. 119, no. 4, pp. 1104–1112, 2000.

[59] P. Hanke, M. Serwe, F. Dombrowski, T. Sauerbruch, and W. H. Caselmann, “DNA vaccination with AFP-encoding plasmid DNA prevents growth of subcutaneous AFP-expressing tumors and does not interfere with liver regeneration in mice,” *Cancer Gene Therapy*, vol. 9, no. 4, pp. 346–355, 2002.

[60] W. S. Meng, L. H. Butterfield, A. Ribas et al., “α-fetoprotein-specific tumor immunity induced by plasmid prime-adenovirus boost genetic vaccination,” *Cancer Research*, vol. 61, no. 24, pp. 8782–8786, 2001.

[61] F. Ghasemi, S. Rostami, M. Ghayour-Mobarhan, and Z. Meshkat, “Current progress in the development of therapeutic vaccines for chronic hepatitis B virus infection,” *Iranian Journal of Basic Medical Sciences*, vol. 19, no. 7, pp. 692–704, 2016.

[62] M. Hirayama and Y. Nishimura, “The present status and future prospects of peptide-based cancer vaccines,” *International Immunology*, vol. 28, no. 7, pp. 319–328, 2016.

[63] X. Wang, Y. Zhou, X. Ying, L. Guo, Y. Zhao, and Y. Fang, “Interaction between heat shock protein 72 and α-fetoprotein in human hepatocellular carcinomas,” *Clinica Chimica Acta*, vol. 379, no. 1-2, pp. 158–162, 2007.

[64] X. Wang, Q. Wang, H. Lin, S. Li, L. Sun, and Y. Yang, “HSP72 and gp96 in gastroenterological cancers,” *Clinica Chimica Acta*, vol. 417, pp. 73–79, 2013.

[65] X.-P. Wang, G.-Z. Liu, A.-L. Song, H.-Y. Li, and Y. Liu, “Antitumor immunity induced by DNA vaccine encoding alpha-fetoprotein/heat shock protein 70,” *World Journal of Gastroenterology*, vol. 10, no. 21, pp. 3977–3020, 2004.
[66] Y.-H. Lan, Y.-G. Li, Z.-W. Liang et al., “A DNA vaccine against chimeric AFP enhanced by HSP70 suppresses growth of hepatocellular carcinoma,” Cancer Immunology, Immunotherapy, vol. 56, no. 7, pp. 1009–1016, 2007.

[67] X.-P. Wang, Q.-X. Wang, H.-P. Lin, Y.-L. Wang, and Y. Yang, “Glycoprotein 96 and α-fetoprotein cross-linking complexes elicited specific antitumor immunity,” Cancer Biotherapy and Radiopharmaceuticals, vol. 28, no. 5, pp. 406–414, 2013.

[68] X.-P. Wang, Q.-X. Wang, H.-P. Lin, B. Xu, Q. Zhao, and K. Chen, “Recombinant heat shock protein 70 functional peptide and alpha-fetoprotein epitope peptide vaccine elicits specific antitumor immunity,” Oncotarget, vol. 7, no. 44, pp. 71274–71284, 2016.

[69] Y. Nakamoto, E. Mizukoshi, M. Kitahara et al., “Prolonged recurrence-free survival following OK432-stimulated dendritic cell transfer into hepatocellular carcinoma during transarterial embolization,” Clinical & Experimental Immunology, vol. 163, no. 2, pp. 165–177, 2011.

[70] F. Tada, M. Abe, M. Hirooka et al., “Phase I/II study of immunotherapy using tumor antigen-pulsed dendritic cells in patients with hepatocellular carcinoma,” International Journal of Oncology, vol. 41, no. 5, pp. 1601–1609, 2012.

[71] L. H. Butterfield, A. Ribas, W. S. Meng et al., “T-cell responses to HLA-A*0201 immunodominant peptides derived from alpha-fetoprotein in patients with hepatocellular cancer,” Clinical Cancer Research, vol. 9, no. 16, part 1, pp. 5902–5908, 2003.

[72] L. H. Butterfield, A. Ribas, V. B. Dissette et al., “A phase I/II trial testing immunization of hepatocellular carcinoma patients with dendritic cells pulsed with four α-fetoprotein peptides,” Clinical Cancer Research, vol. 12, no. 9, pp. 2817–2825, 2006.

[73] Y. Wang, X. Yang, Y. Yu et al., “Immunotherapy of patient with hepatocellular carcinoma using cytotoxic T lymphocytes,” Journal of Cancer, vol. 9, no. 2, pp. 275–287, 2018.

[74] M. R. Hollingdale and M. Sedegah, “Development of whole sporozoite malaria vaccines,” Expert Review of Vaccines, vol. 16, no. 1, pp. 45–54, 2017.

[75] F. Cabillle, O. Toutirais, V. Lavoué et al., “Aminobisphosphonate-pretreated dendritic cells trigger successful Vγ9Vδ2 T cell amplification for immunotherapy in advanced cancer patients,” Cancer Immunology, Immunotherapy, vol. 59, no. 11, pp. 1611–1619, 2010.

[76] M. Ding, Y. Wang, J. Chi et al., “Is adjuvant cellular immunotherapy essential after TACE-predominant minimally-invasive treatment for hepatocellular carcinoma? A systematic meta-analysis of studies including 1774 patients,” PLoS ONE, vol. 11, no. 12, Article ID e0168798, 2016.

[77] A. B. El-Khoueiry, B. Sangro, T. Yau et al., “Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial,” The Lancet, vol. 389, no. 10088, pp. 2492–2502, 2017.